Context: Early-onset obesity, characteristic for disorders affecting the leptin-melanocortin pathway, is also observed in pseudohypoparathyroidism type 1A (PHP1A), a disorder caused by maternal GNAS mutations that disrupt expression or function of the stimulatory G protein a-subunit (Gsa). Mutations and/or epigenetic abnormalities at the same genetic locus are also the cause of pseudohypoparathyroidism type 1B (PHP1B). However, although equivalent biochemical and radiographic findings can be encountered in these related disorders caused by GNAS abnormalities, they are considered distinct clinical entities.
epidemiological studies (3, 4) . PHP1A, which is caused by maternal heterozygous mutations involving those GNAS exons that encode the a-subunit of the stimulatory G protein (Gsa), is usually diagnosed because patients have features of Albright hereditary osteodystrophy (AHO; i.e., developmental delay, short stature, subcutaneous ossifications, round face, brachydactyly, seizures, and mild hypothyroidism) (5) . In addition, a family history positive for either PHP1A or pseudopseudohypoparathyroidism can help establish the diagnosis, although symptoms related to hypocalcemia rarely provide initial evidence for the disease (6) . However, as noted by Fuller Albright in 1942 (7) , excessive weight gain in the first year of life frequently occurs in children affected by PHP1A. It was, therefore, speculated that the metabolic phenotype in PHP1A could be explained by impaired Gsa-dependent signaling of neurotransmitters such as norepinephrine in sympathetic neurons, leading to a reduction of energy expenditure (8, 9) . However, this hypothesis has not been substantiated beyond the initial observations (10) .
In rodent models of PHP1A [i.e., mice with global ablation of maternal Gnas exons 1 or 2 (11, 12) or with a maternal mutation in Gnas exon 6 (V159E) (13) (14) (15) ], central effects on energy metabolism, rather than an increase in food intake, have been documented. Moreover, impaired Gsa-dependent signaling at the melanocortin 4 receptor (MC4R) in the dorsomedial nucleus of the hypothalamus was recently found to be important for regulating energy expenditure and for enhancing brown adipose tissue metabolism but not for promoting food intake (16) , which may involve Gaq/Ga11 signaling (17) .
In proximal renal tubules, the thyroid, the pituitary, parts of the central nervous system, and, possibly, other tissues, Gsa transcription from paternal GNAS is reduced through unknown mechanisms (16, 18) . Because of silenced Gsa expression from this parental allele, maternal loss-of-function mutations involving GNAS exons 1 to 13 are thought to be sufficient to cause resistance to hormones that mediate their actions through different Gsa-coupled receptors. However, the reduction of paternal Gsa expression appears to be variable, because elevations of parathyroid hormone (PTH) and thyroid-stimulating hormone (TSH) develop over time in patients affected by PHP1A or PHP1B (18, 19) and in a murine model of PHP1A (18) . Consistent with variable silencing of paternal Gsa expression in different murine tissues (18, 20, 21) , some studies have provided evidence for reduced energy expenditure in patients with PHP1A (8, 22) ; however, others have attributed the obesity in such patients to hyperphagia (23, 24) . From these findings, it is conceivable that impaired signal transduction occurs at hypothalamic MC4R and/or melanocortin 3 receptor in a subset of patients with PHP1A (23-25), which could lead to an increase in food intake similar to that observed in patients with MC4R or POMC mutations (26) . In addition, growth hormone deficiency (caused by growth hormone-releasing hormone resistance) (27, 28) and mild-to-moderate hypothyroidism (caused by TSH resistance) are likely to contribute to the development of obesity in PHP1A (29, 30) . Thus, multiple independent mechanisms with potentially variable, age-dependent factors could contribute to obesity in PHP1A.
PHP1B is an imprinting disorder caused by maternally inherited deletions involving either STX16 or GNAS that lead to complete methylation changes at one or several differentially methylated regions of the GNAS locus (5, 31, 32) . Gain-of-methylation at exon NESP (neuroendocrine secretory protein 55) and loss-of-methylation at exons AS, XL, and A/B of the maternal GNAS allele has also been observed in sporadic PHP1B cases, which account for most of this disease variant. The cause of the sporadic PHP1B variant is unknown, except for a small number of cases with paternal uniparental isodisomy or heterodisomy of chromosome 20q (patUPD20q) (33) . Patients affected by PHP1B rarely present with characteristic AHO stigmata, and symptomatic hypocalcemia typically occurs after the first decade of life. Until recently, it has been assumed that impaired Gsa signaling occurs only at the PTH receptor, thus leading in PHP1B to clinical symptoms related to abnormal mineral ion homeostasis. However, TSH levels can be elevated in newborns or infants (34) , hyperthyrotropinemia can precede the diagnosis of PHP1B by .1 decade (35) . In addition, accelerated chondrocyte differentiation leads to shortened metacarpals and/or tarsals suggesting that the actions of PTH-related protein in the growth plate are reduced, not only in patients affected by PHP1A but also in some patients with PHP1B (31, (36) (37) (38) . In a few patients, imprinting abnormalities have been observed at several different genetic loci (39) (40) (41) , which can lead to PHP1B combined with BeckwithWiedemann syndrome (BWS) (42) . In the latter patients, BWS was believed to be the main cause for the development of obesity early in life; however, it is conceivable that impaired Gsa signaling was a contributing factor.
Only a few recent case reports have reported childhood obesity as a noticeable finding in patients with PHP1B (42, 43) . Although this could have been a coincidental finding, it is conceivable that early-onset weight gain associated with hyperphagia is an underappreciated sign of PHP1B. In the absence of additional AHO features, even PHP1A might not be considered in the differential diagnosis of obesity early in life. In the present retrospective study, we analyzed the cases of several children who were initially followed clinically, in some cases for many years, because of obesity during infancy and hyperphagia. We furthermore screened a cohort of 24 obese patients for GNAS methylation changes and compared the findings to those observed in several children with a diagnosis of PHP1A. Although early-onset obesity can be a sign of either PHP variant, the prevalence of PHP1B (or PHP1A) among obese patients remains to be determined. However, both disorders should be considered when exploring the cause of pediatric, and possibly, adult obesity.
Materials and Methods
Clinical and laboratory data were obtained from routine investigations, which were performed at obesity and endocrine clinics. Genetic testing for PHP1B was performed in the Endocrine Unit at Massachusetts General Hospital, and all the parents provided written informed consent for genetic testing.
Group 1: patients with obesity as first evidence for sporadic or autosomal dominant PHP1B
Five patients had been referred to pediatric endocrine or obesity clinics because of excessive weight gain and hyperphagia, which had been noted by 3 to 12 months of age. One of these patients (patient 2B) developed clinical signs of hypocalcemia at the age of 14.0 years (i.e., .10 years after the first referral because of obesity), which prompted studies, the results of which suggested the diagnosis of PHP1B. PHP1B had been diagnosed in another patient (patient 3B) shortly after birth because of a positive family history (19) . However, the development of obesity was believed to be unrelated to PHP1B, and she was therefore evaluated further in an obesity clinic.
Because of the previous findings, we selected a group of 24 children from a cohort of 102 consecutive patients with earlyonset obesity to search for GNAS methylation abnormalities. These individuals had been followed at a single center (Charité, Berlin, Germany) because of unexplained obesity that was recognized in the first years of life (age, 0.5 to 3.0 years). Their body mass index ranged from 21 to 28 kg/m 2 , and the individual values were all greater than the 97th percentile. Calcium and PTH levels were not determined as a part of the initial diagnostic evaluation for obesity. With the exception of patient 1B, who had symptomatic hypocalcemia and an elevated PTH level when admitted to his local hospital at the age of 11.5 years, none of the children in this obesity cohort had shown abnormal calcium and phosphate levels during the follow-up period (data not shown).
Group 2: patients with obesity as first evidence for PHP1A
In five patients, initially evaluated because of parental concern of early-onset obesity and impaired growth in some, PHP1A was eventually diagnosed because of AHO features and/or because an older sibling was affected by the same disorder. None of these patients had symptomatic hypocalcemia.
Multiplex ligation-dependent probe amplification and methylation-specific multiplex ligation-dependent probe amplification Genomic DNA was isolated from peripheral blood leukocytes using standard methods. The STX16/GNAS locus was analyzed using multiplex ligation-dependent probe amplification (MLPA) and methylation-specific MLPA, as described previously (32) . Biochemical and endocrine measurements were performed at the participating institutions.
Results
Height and weight data in children with later diagnosis of PHP1A and PHP1B
At birth, patients with a subsequent diagnosis of PHP1A had mean z scores close to the 50th percentile for weight (mean, 20.5; range, 20.2 to 20.9) and for length (mean, 20.4; range, 20.2 to 20.6). In contrast, patients subsequently diagnosed with PHP1B had, at birth, higher z scores for length (mean, +1.4; range, +0.5 to +2.0) and weight (mean, +1.3; range, +0.2 to +2.4), consistent with our previous findings (44) . Subsequently, the mean body mass index remained well above the age-related normal ranges for both groups (z scores, +1.5 to +6.1) but appeared to improve by the end of the first decade of life (Fig. 1) . No appreciable differences were seen between PHP1A and PHP1B regarding the onset and severity of obesity; however, the underlying diagnosis was established .5 years earlier for PHP1A patients (Table 1) . For some patients, the longitudinal measurements of body weight remained well above the reference range for the entire observation period, despite close medical monitoring, dietary efforts, and/or enrollment in childhood obesity programs. All the parents expressed concern that obesity in their children was caused by considerable hyperphagia.
TSH resistance and initiation of therapy with L-thyroxine
With the exception of one patient (patient 5A), the PHP1A cohort revealed elevated serum TSH levels and low serum free thyroxine (fT4)/total thyroxine (TT4) concentrations when first evaluated for obesity (Table 1) . Therapy with L-thyroxine was therefore initiated. Furthermore, in six of the seven patients with PHP1B, hypothyroidism was suspected because of increased TSH levels during the workup for obesity and despite normal fT4/TT4 concentrations; treatment with thyroid hormone was started in five patients aged 6 months to 3 years (i.e., well before the diagnosis of PHP1B was established). However, for both groups of patients, this therapeutic intervention failed to slow the weight gain.
Analysis of epigenetic and genetic changes at the GNAS/STX16 locus
In all patients, the diagnosis of PHP1A and PHP1B was confirmed by genetic testing. The calcium and phosphate levels were either normal or were not measured as a part of the initial obesity workup for most patients, in whom PHP1B was later diagnosed.
Because of obesity combined with elevated TSH levels, PHP1A was considered to be the underlying diagnosis in patients 1A, 2A, and 4A, although their mothers revealed no evidence of AHO. The PTH level was tested in only one patient with PHP1A (patient 3A) when first evaluated for obesity. This test was performed largely because of an equally affected older sibling (patient 2A), who had recently received the same diagnosis. Three different mutations in GNAS exons 7, 12, and 13 were identified in this cohort of patients, confirming their clinical diagnosis (Table 1) .
For siblings 4B and 5B, both affected by PHP1B, sequence analysis of GNAS exons 1 to 13 was negative. Instead, complete loss-of-methylation at the differentially methylated region of GNAS exon A/B was noted. This epigenetic abnormality led to the identification of the 3-kb STX16 deletion in both children, which had been inherited from their unaffected mother and maternal grandfather (data not shown). Deletions in GNAS/STX16 could not be identified for patients 2B and 6B (35) , but both showed loss-of-methylation at exons A/B, XL, and AS, and gain-ofmethylation at exon NESP. Patient 3B was an affected member of a previously reported AD-PHP1B kindred and just as other affected family members, she had inherited the 4.4-kb STX16 deletion from an unaffected mother, thus explaining her elevated PTH level by 2 years of age (19) . However, at that time, early-onset obesity was thought to be unrelated to PHP1B, and she therefore underwent independent evaluations in an obesity clinic.
Screening for GNAS methylation variants in unselected children with early-onset obesity
Because of these findings, we hypothesized that hyperphagia leading to severe obesity in the first year of life might be an as-yet unrecognized symptom of PHP1B. We therefore investigated the cases of 24 patients, randomly selected from a cohort of 102 obese children, who had been evaluated at a single obesity clinic (Charité, Berlin, Germany). The exons encoding MC4R and POMC were sequenced in 10 individuals, including patient 7B; however, no genetic abnormality was detected (data not shown). Patients 1B and 7B showed a loss-of-methylation at GNAS exon A/B and MLPA revealed only one copy of STX16 exons 4 and 5, which led to the identification of the frequent 3-kb STX16 deletion ( Table 1 ).
The mothers of both patients revealed the same deletion, as determined by polymerase chain reaction (PCR) of their genomic DNA, but they showed no GNAS methylation abnormalities indicating that their deletion resides on the paternal allele (data not shown). MLPA revealed only a barely detectable, very incomplete, loss of STX16 exons 4 and 5 for the mother of patient 1B (Supplemental Fig. 1 ). Consistent with this observation, analysis of microsatellite 261P9-CA1 documented heterozygosity for this marker (mother, alleles 206 and 216; patient, only allele 210). The forward primer for amplification of this microsatellite is located within the 3-kb STX16 deletion, and the reverse primer resides outside this mutation. Although the 3-kb STX16 deletion was readily detectable by PCR, the identification of two maternal 261P9-CA1 alleles not shared with patient 1B indicated that the patient's mother has a de novo mosaic deletion.
After identification of the genetic defect for patient 1B, a review of his more recent medical records revealed that he had been admitted to a local hospital at the age of Figure 1 . Early-onset obesity in PHP1A and PHP1B. Individual body mass index z scores and mean values (horizontal lines) at different ages of children affected by (left) PHP1A (n = 5) and (right) PHP1B (n = 7; Student t test with Welch correction: no significant differences between both groups). Note that most patients were monitored at their respective clinics several times within each age bracket; thus, several independent measurements were obtained. doi: 10.1210/jc.2017-00395 https://academic.oup.com/jcem11.5 years because of symptomatic hypocalcemia and an elevated PTH level, suggesting PTH resistance. Patient 7B had had no calcium or phosphate abnormalities found during routine follow-up examinations; however, after establishment of the genetic defect when he was 5.5 years old, the laboratory studies were repeated, and asymptomatic hypocalcemia and an elevated PTH level (86 ng/L) were noted. His leptin level was 20.0 ng/mL (normal, 3 to 21). MLPA and methylation-specific MLPA provided no evidence for abnormalities for the remaining 22 children.
Discussion
Early-onset obesity had brought several infants to medical attention, long before the diagnosis of PHP1A or PHP1B was considered. In fact, excessive weight gain preceded other clinical or laboratory signs of these related diseases, in some patients with PHP1B by more than one decade. Only for two patients (patients 1B and 2B) was the diagnosis of PHP1B considered because of clinically symptomatic hypocalcemia with elevated PTH serum levels at age 11.5 and 14.0 years, respectively. In both cases, no AHO features other than obesity were present. PHP1A was initially considered for siblings 4B and 5B. However, instead of a mutation involving GNAS exons 1 to 13, the frequent 3-kb STX16 deletion was identified, establishing the diagnosis of PHP1B. Likewise, STX16 deletions were found in patients 1B, 3B, and 7B, and patients 2B and 6B showed broad GNAS methylation changes. For the two latter patients, the underlying genetic defect could not be determined; however, paternal uniparental isodisomy involving a large portion of Laboratory results were obtained from clinical laboratories at the different participating centers; TT4, instead of fT4, was therefore available for some patients. Boldface indicates whether a patient was affected by PHP1A or PHP1B.
Abbreviations: GOM, gain-of-methylation; LOM, loss-of-methylation; LT4, levothyroxine; NA, not applicable; ND, not determined; NP, not published. a Data for calculating mean values were included only if gestational age was .35 weeks.
b Excluded from calculation of mean age at diagnosis.
c Ionized calcium was measured in some centers, and others measured total calcium.
d Treated with Rocaltrol and CaCO 3 for only a short period; treated continuously after 2.5 years of age.
chromosome 20q was excluded through analysis of six microsatellite markers (data not shown) (32, 35) . The five patients with a diagnosis of PHP1A had been referred primarily because of obesity, but brachydactyly and subcutaneous calcifications were initially not noted. Also, their mothers showed no obvious evidence for pseudopseudohypoparathyroidism. BWS or Prader-Willi syndrome was suspected in one patient; however, both disorders were ruled out through genetic analyses (data not shown). Two PHP1A patients had older siblings affected by the same disease, and both sibpairs had developed obesity in the first year of life despite intensive dietary counseling. Our findings have demonstrated that PHP1A and, surprisingly, PHP1B can be indistinguishable entities with regard to early-onset obesity. This shared metabolic phenotype is most likely caused by silenced paternal Gsa expression in those parts of the central nervous system that contribute to the regulation of food intake and energy expenditure, combined with globally absent or diminished maternal Gsa expression due to genetic or epigenetic GNAS changes. Consequently, as yet undefined tissues or cells are likely to show in our patients a major reduction of Gsa expression and . thus profound cyclic adenosine monophosphate deficiency, leading to abnormal weight regulation.
All parents were concerned that the obesity of their children was related to their impressive increase in appetite. It is, therefore, conceivable that resistance at the hypothalamic Gsa-coupled MC4R and/or melanocortin 3 receptor contributes significantly to the excessive weight gain in patients with PHP1A (23, 24) and patients with PHP1B, as suggested by a recently reported case (43) . It remains to be determined, however, whether additional abnormalities such as abnormal Gq/G11-dependent signaling at the MC4R contribute to obesity in PHP1A or PHP1B patients, as suggested for rodents (17) .
Most patients in whom PHP1B and PHP1A were diagnosed later had an elevated TSH level well before an increased PTH level was documented. However, the fT4/ TT4 levels were only slightly reduced or low-normal, making it unlikely that subclinical hypothyroidism was responsible for the development of early-onset obesity. The association between increased TSH levels and obesity, which was encountered in six of our seven patients with PHP1B, confirms that impaired Gsa-dependent signaling is not always restricted to the proximal renal tubules.
Unlike PHP1A, PHP1B due to maternal STX16 deletions is associated with increased weights and lengths at birth (44) . These genetic mutations cause loss-ofmethylation at GNAS exon A/B alone, which is sufficient to impair maternal Gsa expression (45) . Biallelic expression of A/B or another GNAS-derived transcript could be responsible for these observations during fetal growth and similar mechanisms could affect postnatal energy metabolism and longitudinal growth. Moreover, generalized imprinting disorders can lead to overlapping epigenetic findings, as described for a patient with clinical and laboratory features of BWS and PHP1B (42) , making it difficult to distinguish these disorders by the clinical symptoms alone. It is therefore conceivable that our two PHP1B patients with broad GNAS methylation changes (patients 2B and 6B) could harbor additional epigenetic changes elsewhere, including methylation changes at the variably methylated region located at the intron 2-exon 3 border of POMC that influence body weight regulation (46) . However, five of the seven patients with PHP1B revealed the well-established, disease-causing deletion in STX16, making it unlikely that additional genetic mutations contributed to abnormal regulation of appetite and body weight homeostasis in these patients.
Patients with an onset of excessive obesity within the first year of life should be regarded as having a high risk of monogenic disorders, including mutations involving GNAS exons 1 to 13 and, as shown in the present study, epigenetic changes at this complex locus. Establishing the diagnosis of PHP1A and PHP1B in patients with earlyonset obesity is important for genetic counseling and parental support. Furthermore, both disorders could potentially provide additional treatment options, such as phosphodiesterase inhibitors to enhance the actions of limited amounts of cyclic adenosine monophosphate derived from the paternal allele or novel MC4R agonists to overcome the partial resistance at the melanocortin receptors in the paraventricular nucleus (2) . The number of children with PHP1B followed up longitudinally after birth has been limited owing to the rarity of the disease. However, as shown in the present study, the prevalence of genetic and epigenetic GNAS changes as the cause of obesity might have been underestimated, because TSH elevations and early-onset obesity failed to prompt further diagnostic evaluation of our PHP1B patients. Furthermore, reduced paternal Gsa expression can occur in additional tissues or cell types, thus leading to other, potentially unrecognized features in the presence of maternal GNAS defects. Larger patient cohorts need to be investigated to determine whether abnormalities other than early-onset obesity and impaired TSH signaling can be identified in PHP1B patients before the development of PTH-resistant hypocalcemia, and whether features such as obesity might be the only evidence of impaired Gsadependent signaling.
Measurement of PTH and TSH should be considered for all children with substantial early-onset obesity in the first year of life. However, the level of either hormone may not be elevated during infancy or throughout life (18, 19, 47 ) and thus will not necessarily be helpful in establishing the diagnosis for all PHP1B cases. Furthermore, DNA sequencing approaches are usually not designed to detect methylation variants and might not detect small deletions or genomic rearrangements. A targeted search for genetic and epigenetic GNAS variants will therefore be necessary to reliably exclude abnormalities in this complex genetic locus, in particular if unexplained obesity is present during infancy, but also later in life. Laboratory testing should be performed to confirm the diagnosis.
